Exact Mass: 383.19573
Exact Mass Matches: 383.19573
Found 500 metabolites which its exact mass value is equals to given mass value 383.19573,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Prazosin
C19H21N5O4 (383.15934660000005)
Prazosin is a selective α-1-adrenergic receptor antagonist used to treat hypertension. It has also been used to decrease urinary obstruction and relieve symptoms associated with symptomatic benign prostatic hyperplasia. α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. Prazosin has also been used in conjunction with cardiac glycosides and diuretics in the management of severe congestive heart failure. It has also been used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma. C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents KEIO_ID P191; [MS2] KO009165 Corona-virus KEIO_ID P191 Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder. It is an alpha-adrenergic blocker that is specific for the alpha-1 receptors. These receptors are found on vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine. They are also found throughout the central nervous system. As of 2013, prazosin is off-patent in the US, and the FDA has approved at least one generic manufacturer.In addition to its alpha-blocking activity, prazosin is an antagonist of the MT3 receptor (which is not present in humans), with selectivity for this receptor over the MT1 and MT2 receptors. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is initially started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases.
Quetiapine
The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; Quetiapine belongs to a series of neuroleptics known as "atypical antipsychotics", which have become increasingly popular alternatives to "typical antipsychotics" such as haloperidol. Quetiapine HAS approvals for the treatment of schizophrenia and acute mania in bipolar disorder. It is also used off-label to treat other disorders, such as post-traumatic stress disorder, alcoholism, obsessive compulsive disorder, anxiety disorders, hallucinations in Parkinsons disease patients using ropinirole, and as a sedative for those with sleep disorders. The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; for the same reason, abuse of other antipsychotics, such as chlorpromazine (Thorazine), may occur as well, but research related to the abuse of typical antipsychotics is limited. for the same reason, abuse of other antipsychotics, such as chlorpromazine (Thorazine), may occur as well, but research related to the abuse of typical antipsychotics is limited. The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; Quetiapine belongs to a series of neuroleptics known as "atypical antipsychotics", which have become increasingly popular alternatives to "typical antipsychotics" such as haloperidol. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].
Dihydrozeatin-O-glucoside
Dihydrozeatin-O-glucoside belongs to the class of organic compounds known as fatty acyl glycosides of mono- and disaccharides. Fatty acyl glycosides of mono- and disaccharides are compounds composed of a mono- or disaccharide moiety linked to one hydroxyl group of a fatty alcohol, a phosphorylated alcohol (phosphoprenol), or a hydroxy fatty acid, or to one carboxyl group of a fatty acid (ester linkage) or an amino alcohol. Dihydrozeatin-O-glucoside is an extremely weak basic (essentially neutral) compound (based on its pKa). Dihydrozeatin-O-glucoside is the product of the O-glucosylation of dihydrozeatin in the cytokinin O-glucosylation. The O-glucosylation is reversible and resistant to beta-glucosidases. This reaction only shuts the physiological activity of the molecule temporarily, and is a way to store a molecule. A human metabolite taken as a putative food compound of mammalian origin [HMDB]. Dihydrozeatin-O-glucoside is found in many foods, some of which are tarragon, swede, mamey sapote, and oil-seed camellia.
Deoxyaureothin
A 4-pyranone that is 2-methoxy-3,5-dimethyl-4H-pyran-4-one which is substituted at position 6 by a 2,4-dimethyl-1-(p-nitrophenyl)hexa-1,3-dien-6-yl group (the E,E isomer).
Sacubitrilat
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
Meropenem
C17H25N3O5S (383.15148400000004)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DH - Carbapenems D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Meropenem (SM 7338) is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL)[1][2].
Dihydrozeatin-9-N-glucoside
Dihydrozeatin-9-N-glucoside belongs to the class of organic compounds known as glycosylamines. Glycosylamines are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether). Dihydrozeatin-9-N-glucoside is possibly neutral. Dihydrozeatin-9-N-glucoside is involved in cytokinin 9-N-glucoside biosynthesis and is also involved in cytokinin-O-glucoside biosynthesis as a precursor to dihydrozeatin-9-N-glucoside-O-glucoside. N-Glucosylation at the 9-position is similar to the N-glucosylation at the 7-position. A human metabolite taken as a putative food compound of mammalian origin [HMDB]. Dihydrozeatin-9-N-glucoside is found in many foods, some of which are tronchuda cabbage, pear, persian lime, and turmeric.
Niazimin
Niazimin is a glucosinolate and a naturally occurring carbamate. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables. The cis and trans rotamers of niazimin (niazimin A and niazimin B, respectively) differ in the orientation of the NH group with respect to the carbonyl group. Constituent of Moringa oleifera (horseradish tree). Niazimin A is found in fats and oils, herbs and spices, and green vegetables.
Dihydrozeatin-7-N-glucoside
Dihydrozeatin-7-N-glucoside (CAS: 91599-03-0) belongs to the class of organic compounds known as glycosylamines. Glycosylamines are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether). Dihydrozeatin-7-N-glucoside is a strong basic compound (based on its pKa). Dihydrozeatin-7-N-glucoside is involved in cytokinin 7-N glucoside biosynthesis in plants as a product of the N-glucosylation of dihydrozeatin by UDP-glucose. When plants are exposed to a high concentration of cytokinins many are conjugated into 7-N glucosides. The addition to the N position decreases the physiological activity of the cytokine. Therefore, N-glucosylation may be a strategy of detoxification for plants. N-Glucosylation is common in radish.
Meropenem
C17H25N3O5S (383.15148400000004)
Meropenem is only found in individuals that have used or taken this drug.It is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding- protein (PBP) targets and interfere with the synthesis of the vital cell wall components, which leads to cell death. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DH - Carbapenems D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Meropenem (SM 7338) is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL)[1][2].
(1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol
N-(1-Adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
3-[5-(Dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
C17H25N3O5S (383.15148400000004)
N-[(1R)-2,3-Dihydro-1H-inden-1-yl]-adenosine
C19H21N5O4 (383.15934660000005)
Anagliptin
L-Proline, 1-(N-((3-((propylamino)carbonyl)oxiranyl)carbonyl)-L-isoleucyl)-, (2S-trans)-
C18H29N3O6 (383.20562540000003)
3-((2'-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine
LEUCOGENENOL
Losmapimod
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2149 - Mitogen-Activated Protein Kinase Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate
C21H22FN3O3 (383.16451140000004)
Propiverine N-oxide
C23H29NO4 (383.20964740000005)
Tandospirone
Tilsuprost
C20H33NO4S (383.2130178000001)
Trecadrine
VERALIPRIDE
C17H25N3O5S (383.15148400000004)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AL - Benzamides C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.
N'-[2-(Oxidanylcarbamoyl)phenyl]-N-phenyl-octanediamide
Dihydrozeatin O-beta-D-Glucoside
Dihydrozeatin o-beta-d-glucoside is a member of the class of compounds known as fatty acyl glycosides of mono- and disaccharides. Fatty acyl glycosides of mono- and disaccharides are compounds composed of a mono- or disaccharide moiety linked to one hydroxyl group of a fatty alcohol or of a phosphorylated alcohol (phosphoprenols), a hydroxy fatty acid or to one carboxyl group of a fatty acid (ester linkage) or to an amino alcohol. Dihydrozeatin o-beta-d-glucoside is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Dihydrozeatin o-beta-d-glucoside can be found in soy bean, which makes dihydrozeatin o-beta-d-glucoside a potential biomarker for the consumption of this food product.
Niazimin A
Constituent of Moringa oleifera (horseradish tree). Niazimin A is found in fats and oils, herbs and spices, and green vegetables.
N,N-Dimethyl-2-(1,2,3-trimethoxynaphtho(2,1-f)(1,3)benzodioxol-4-yl)ethanamine
Daphnilongeranin A
C23H29NO4 (383.20964740000005)
2-(2,3-Dimethoxyphenyl)-5,8-dimethoxy-3-propyl-4(1H)-quinolinone
1-[1-(3,4-Dichlorobenzamidomethyl)cyclohexyl]-4-methylpiperazine
3,4-dimethoxy-6,13-dimethyl-5,7,8,15-tetrahydro-6H-benzo[c][1,3]dioxolo[4,5:4,5]benzo[1,2-g]azecin-14-one
12,13,19-trihydroxy-15,20-epoxy-15,20-dihydro, (12S,15R,20R)senecionan-11,16-dione|15,20-Epoxy-15,20-dihydro-12,13,19-trihydroxy-11,16-senecionanedione|Adonifoline
9-(3-isovaleryl)viridifloryl retronecine
C20H33NO6 (383.23077580000006)
6-[(Isopropyloxy)methyl]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one
9H-Purin-6-amine, N-(3-methylbutyl)-2-(methylthio)-9-pentofuranosyl-
C16H25N5O4S (383.16271700000004)
3,7-diacetyl-intermedine|3,7-Diacetylintermedine|3,7-Diacetyllycopsamine|Di-O-acetylindicin
Nb-methyl-3alpha-amino-seco-voacarpine
C22H29N3O3 (383.22088040000006)
5,8-dimethoxy-2-(3,4-dimethoxyphenyl)-3-propyl-1h-quinolin-4-one
(+)-lanatine A|(4S,6R,7S,13S)-13-oxyanthranoyllupanine
C22H29N3O3 (383.22088040000006)
(7Xi,8S)-8,6,7-trimethoxy-2-methyl-6,8,3,4-tetrahydro-2H-spiro[indeno[4,5-d][1,3]dioxole-7,1-isoquinoline]|Fumaritrin
Me glycoside,N,4-O-dibenzoyl-beta-L-Pyranose-3-Amino-2,3,6-trideoxy-3-C-methyl-xylo-hexose
N-[2-(7-Hydroxy-3,4,6-trimethoxyphenanthren-1-yl)ethyl]-N-methylacetamide
Me glycoside,N,4-dibenzoyl-alpha-L-Pyranose-3-Amino-2,3,6-trideoxy-3-C-methyl-xylo-hexose
Spiramide
Spiramide is an azaspiro compound that consists of 1,3,8-triazaspiro[4.5]decan-4-one having a phenyl group attached to N-1 and a 3-(4-fluorophenoxy)propyl attached to N-8. Selective 5-HT antagonist, which binds to 5-HT2 sites as potently as spiperone but has lower affinity for 5-HT2C receptors. Also a high affinity D2 receptor antagonist (Ki = 3 nM). Lacks the disruptive effect of spiperone on animal behaviour. It has a role as a dopaminergic antagonist and a serotonergic antagonist. It is an azaspiro compound, an organofluorine compound, an aromatic ether, a tertiary amino compound and a member of piperidines. Spiramide is a natural product found in Spiraea japonica with data available. C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Spiramide (AMI-193) is a potent and selective antagonist of 5-HT2 and dopamine D2 receptor, with Kis of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT2 versus 5-HT1C (Ki=4300 nM) receptors. Spiramide exhibits antipsychotic activity[1][2][3]. Spiramide (AMI-193) is a potent and selective antagonist of 5-HT2 and dopamine D2 receptor, with Kis of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT2 versus 5-HT1C (Ki=4300 nM) receptors. Spiramide exhibits antipsychotic activity[1][2][3]. Spiramide (AMI-193) is a potent and selective antagonist of 5-HT2 and dopamine D2 receptor, with Kis of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT2 versus 5-HT1C (Ki=4300 nM) receptors. Spiramide exhibits antipsychotic activity[1][2][3].
prazosin
C19H21N5O4 (383.15934660000005)
C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS relative retention time with respect to 9-anthracene Carboxylic Acid is 0.767 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.759 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.760 Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder. It is an alpha-adrenergic blocker that is specific for the alpha-1 receptors. These receptors are found on vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine. They are also found throughout the central nervous system. As of 2013, prazosin is off-patent in the US, and the FDA has approved at least one generic manufacturer.In addition to its alpha-blocking activity, prazosin is an antagonist of the MT3 receptor (which is not present in humans), with selectivity for this receptor over the MT1 and MT2 receptors. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is initially started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases.
(6aS)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-3-carbaldehyde
relative retention time with respect to 9-anthracene Carboxylic Acid is 0.778 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.773
6,7-Dimethoxy-1-[2-(2,3,4-trimethoxy-phenyl)-vinyl]-3,4-dihydro-isoquinoline
C22H25NO5_(3R,4R)-4,5-Dihydroxy-3-methoxy-4-(4-methoxyphenyl)-6-(3-methyl-2-buten-1-yl)-3,4-dihydro-2(1H)-quinolinone
C19H33N3O5_2,8-Diisobutyl-5-methyl-1-oxa-4,7,10-triazacyclotetradecane-3,6,9,14-tetrone
C19H33N3O5 (383.24200880000006)
quetiapine
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].
18-Aminoabieta-8,11,13-Triene Sulfate
C20H33NO4S (383.2130178000001)
VERALIPRIDE
C17H25N3O5S (383.15148400000004)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AL - Benzamides C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.
Gly Gly His Asn
C14H21N7O6 (383.15532460000003)
Gly Gly Asn His
C14H21N7O6 (383.15532460000003)
Gly His Gly Asn
C14H21N7O6 (383.15532460000003)
Gly His Asn Gly
C14H21N7O6 (383.15532460000003)
Gly Asn Gly His
C14H21N7O6 (383.15532460000003)
Gly Asn His Gly
C14H21N7O6 (383.15532460000003)
Gly Asn Pro Pro
Gly Pro Asn Pro
Gly Pro Pro Asn
His Gly Gly Asn
C14H21N7O6 (383.15532460000003)
His Gly Asn Gly
C14H21N7O6 (383.15532460000003)
His Asn Gly Gly
C14H21N7O6 (383.15532460000003)
Asn Gly Gly His
C14H21N7O6 (383.15532460000003)
Asn Gly His Gly
C14H21N7O6 (383.15532460000003)
Asn Gly Pro Pro
Asn His Gly Gly
C14H21N7O6 (383.15532460000003)
Asn Pro Gly Pro
Asn Pro Pro Gly
Pro Gly Asn Pro
Pro Gly Pro Asn
Pro Asn Gly Pro
Pro Asn Pro Gly
Pro Pro Gly Asn
Pro Pro Asn Gly
Platelet-activating factor
1-Octanoyllysolecithin
PC(8:0/0:0)[U]
PC(0:0/8:0)[U]
N-Boc-4-[2-(4-Toluenesulfonyloxy)ethyl]piperidine
C19H29NO5S (383.17663440000007)
PD 117519
C19H21N5O4 (383.15934660000005)
PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models[1][2]. PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models[1][2].
1-(diphenylmethyl)azetidin-3-yl 2-carbamimidoylacetate acetate
tert-Butyl (3R,4R)-4-(4-benzyloxyphenyl)-3-hydroxypiperidine-1-carboxylate
C23H29NO4 (383.20964740000005)
1-Piperidinecarboxylic acid, 4-[4-[[(2-hydroxy-1,1-dimethylethyl)amino]carbonyl]-2-oxo-1-pyrrolidinyl]-, 1,1-dimethylethyl ester
C19H33N3O5 (383.24200880000006)
CA 074 TFA
C18H29N3O6 (383.20562540000003)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D020011 - Protective Agents
Tandospirone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Tandospirone (SM-3997) is a potent and selective 5-HT1A receptor partial agonist, with a Ki of 27 nM. Tandospirone has anxiolytic and antidepressant activities. Tandospirone can be used for the research of the central nervous system disorders and the underlying mechanisms[1][2][3].
1-Piperidinecarboxylic acid, 3-hydroxy-4-[4-(phenylmethoxy)phenyl]-, 1,1-dimethylethyl ester, trans
C23H29NO4 (383.20964740000005)
Anagliptin
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid
C23H29NO4 (383.20964740000005)
Benzododecinium Bromide
D013501 - Surface-Active Agents > D003902 - Detergents > D001548 - Benzalkonium Compounds C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D000890 - Anti-Infective Agents D004202 - Disinfectants
FMOC-(2S,3S)-3-AMINO-2-HYDROXY-5-METHYLHEXANOIC ACID
1-(Diphenylmethyl)-3-azetidinyl 3,3-diaminoacrylate acetate (1:1)
6-[(2-Nitrophenyl)azo]-2,4-di-tert-pentylphenol
C22H29N3O3 (383.22088040000006)
N-(1-(2-(1H-INDOL-3-YL)ETHYL)PIPERIDIN-4-YL)BENZAMIDE HYDROCHLORIDE
C22H26ClN3O (383.17642960000006)
(2S,4S)-5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid
C23H29NO4 (383.20964740000005)
(2S,4R)-5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid
C23H29NO4 (383.20964740000005)
9-(3-Methylphenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole
(3,3,4,4,4-D5)-(E/Z)-1-[4-(2-CHLOROETHOXY)PHENYL]-1-[4-HYDROXYPHENYL]-2-PHENYL-1-BUTENE
C24H18ClD5O2 (383.17003468999997)
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9-(p-tolyl)-9H-carbazole
4-(trans-4-Propylcyclohexyl)benzoic acid 4-cyano-3,5-difluorophenyl ester
C23H23F2NO2 (383.16967619999997)
[3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrol-1-yl]-tri(propan-2-yl)silane
Cetylpyridinium Bromide
C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent
(Methylpyridazine piperidine propyloxyphenyl)ethylacetate
C22H29N3O3 (383.22088040000006)
Technetium tc 99m exametazime
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D019275 - Radiopharmaceuticals C1446 - Radiopharmaceutical Compound > C2124 - Radioconjugate
3-((2-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine
D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers
Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-DL-valinate
C21H22FN3O3 (383.16451140000004)
N-((1-(2-(tert-Butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Panicutine
C23H29NO4 (383.20964740000005)
A natural product found in Aconitum paniculatum and Delphinium denudatum.
3-(2-Hydroxy-4,6-dimethoxyphenyl)-1-(3-methyl-1-piperidinyl)-3-phenyl-1-propanone
C23H29NO4 (383.20964740000005)
N-({(2S)-1-[(3R)-3-Amino-4-(2-fluorophenyl)butanoyl]pyrrolidin-2-YL}methyl)benzamide
N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine
C17H25N3O5S (383.15148400000004)
(2s)-1-{[5-(1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-[(7as)-7ah-Indol-3-Yl]propan-2-Amine
Losmapimod
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2149 - Mitogen-Activated Protein Kinase Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(1,4a-Dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl)methanamine;sulfuric acid
C20H33NO4S (383.2130178000001)
(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine
C22H27N2O4+ (383.19707220000004)
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-(7H-purin-6-ylamino)butoxy]oxane-3,4,5-triol
N-acetyl-beta-D-glucosaminyl-(1->4)-D-glucosaminium(1+)
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[6-[[(3S)-4-hydroxy-3-methylbutyl]amino]purin-9-yl]oxane-3,4,5-triol
(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-1-ium-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
C17H25N3O5S (383.15148400000004)
3-Epoxy-16-methoxy-2,3-dihydrotabersonine
C22H27N2O4+ (383.19707220000004)
(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-(7H-purin-6-ylamino)butoxy]oxane-3,4,5-triol
(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[6-[[(3S)-4-hydroxy-3-methylbutyl]amino]purin-9-yl]oxane-3,4,5-triol
2-(1-Imidazolyl)-4-phenyl-6-(4-phenyl-1-piperazinyl)-1,3,5-triazine
2-(3,5-Diphenyl-3,4-dihydropyrazol-2-yl)-2-(4-hydroxy-3-methoxyphenyl)acetonitrile
7-(Diethylaminomethyl)-1-(4-methoxyphenyl)-2-methyl-3-nitro-6-indolol
3-(1-methyl-1H-pyrrol-2-yl)-N-[(E)-(2,4,5-trimethoxyphenyl)methylidene]-1H-pyrazole-5-carbohydrazide
C19H21N5O4 (383.15934660000005)
6,7-dimethoxy-1-[(E)-2-(2,3,4-trimethoxyphenyl)ethenyl]-3,4-dihydroisoquinoline
N-[1-(cyclohexylamino)-2-methyl-1-oxobutan-2-yl]-N-(2-furanylmethyl)-2-pyridinecarboxamide
C22H29N3O3 (383.22088040000006)
N-[2-[4-(dimethylamino)phenyl]-2-(1H-indol-3-yl)ethyl]benzamide
N-butyl-N-methyl-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide
1-[[1-(4-Methoxyphenyl)-3-pyrrolidinyl]methyl]-3-(2,4,6-trimethylphenyl)thiourea
C22H29N3OS (383.20312240000004)
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(dimethylamino)methyl]-N-(3-phenylpropylideneamino)-4-triazolecarboxamide
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine
2-(3-isopropyloxyphenyl)-N-(pyridin-4-yl)quinoline-4-carboxamide
16alpha-Hydroxydehydroepiandrosterone 3-sulfate(1-)
C19H27O6S- (383.15282620000005)
A steroid sulfate oxoanion that is the conjugate base of 16alpha-hydroxydehydroepiandrosterone 3-sulfate, arising from deprotonation of the sulfate OH group; major species at pH 7.3.
N-(1-tert-butyl-5-benzimidazolyl)-3,4,5-trimethoxybenzamide
1-[(4-Methoxy-3-phenylmethoxyphenyl)methyl]-4-piperidinecarboxylic acid ethyl ester
C23H29NO4 (383.20964740000005)
5-(3,4-Dimethoxyphenyl)-2-methyl-4-(4-methyl-1-piperidinyl)thieno[2,3-d]pyrimidine
2-(3,5-Dimethyl-1-pyrazolyl)-1-[3-[oxo-(3-propan-2-yloxyphenyl)methyl]-1-piperidinyl]ethanone
C22H29N3O3 (383.22088040000006)
(2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
C22H29N3O3 (383.22088040000006)
2-octanoyl-sn-glycero-3-phosphocholine
A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as octanoyl.
N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide
C19H33N3O5 (383.24200880000006)
N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide
C19H33N3O5 (383.24200880000006)
N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide
C19H33N3O5 (383.24200880000006)
N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide
C19H33N3O5 (383.24200880000006)
(2S,3S,3aR,9bR)-7-(cyclohexen-1-yl)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
C22H29N3O3 (383.22088040000006)
N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]ethyl]cyclobutanecarboxamide
C19H33N3O5 (383.24200880000006)
N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]ethyl]cyclobutanecarboxamide
C19H33N3O5 (383.24200880000006)
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3-oxanyl]cyclopropanecarboxamide
C19H33N3O5 (383.24200880000006)
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide
C17H25N3O5S (383.15148400000004)
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide
C17H25N3O5S (383.15148400000004)
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide
C17H25N3O5S (383.15148400000004)
N-[[(2R,3R,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(2R,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide
(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C22H29N3O3 (383.22088040000006)
(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C22H29N3O3 (383.22088040000006)
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide
C17H25N3O5S (383.15148400000004)
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide
C17H25N3O5S (383.15148400000004)
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide
C17H25N3O5S (383.15148400000004)
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide
C17H25N3O5S (383.15148400000004)
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide
C17H25N3O5S (383.15148400000004)
N-[[(2S,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide
(1R,5S)-7-[4-(3-methylphenyl)phenyl]-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide
1-[(1S,5R)-7-[4-(2-methylphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-2-pyridin-4-ylethanone
cyclobutyl-[(1S)-1-(hydroxymethyl)-7-methoxy-2,9-dimethyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanone
C22H29N3O3 (383.22088040000006)
cyclobutyl-[(1R)-1-(hydroxymethyl)-7-methoxy-1-spiro[1,2,3,9-tetrahydropyrido[3,4-b]indole-4,4-piperidine]yl]methanone
C22H29N3O3 (383.22088040000006)
cyclobutyl-[(1R)-1-(hydroxymethyl)-7-methoxy-2,9-dimethyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanone
C22H29N3O3 (383.22088040000006)
5-Amino-5-(4-hydroxybenzyl)-6-((2,3,4,5-tetrahydroxypentyl)amino)dihydropyrimidine-2,4-dione(1+)
(4R,5S,6R)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
C17H25N3O5S (383.15148400000004)
(5S,6Z,8E,10E,12R,14Z)-5,12,20,20,20-pentahydroxyicosa-6,8,10,14-tetraenoate
(E,8R)-8-[(2R,3R,5R,6S)-3-hydroxy-6-methyl-5-[(E)-2-methylbut-2-enoyl]oxyoxan-2-yl]oxynon-2-enoate
N-[(2S)-2-hydroxy-2-(1,2,3,4-tetrahydronaphthalen-2-ylamino)ethyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] undecanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] acetate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] propanoate
(3-Acetyloxy-2-pentanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C15H30NO8P (383.17089500000003)
(2-Butanoyloxy-3-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C15H30NO8P (383.17089500000003)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] hexanoate
C15H30NO8P (383.17089500000003)
[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] octanoate
C15H30NO8P (383.17089500000003)
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-pentanoyloxypropyl] pentanoate
C15H30NO8P (383.17089500000003)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] heptanoate
C15H30NO8P (383.17089500000003)
2-[(2-Acetamido-3-hydroxynonoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(propanoylamino)octoxy]phosphoryl]oxyethyl-trimethylazanium
7-(alpha-D-glucosyl)dihydrozeatin
An N-glycosyldihydrozeatin in which the glycosyl fragment is an alpha-D-glucopyranosyl residue located at position 7.
3-[5-(Dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
C17H25N3O5S (383.15148400000004)
soppiline C(1-)
A hydroxy monocarboxylic acid anion that is the conjugate base of soppiline C, arising from the deprotonation of the carboxy group. Major species at pH 7.3.
(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersoninium
C22H27N2O4 (383.19707220000004)
An indole alkaloid cation that is the conjugate acid of (3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine, obtained by protonation of the tertiary amino group. Major species at pH 7.3.
PE(10:0)
C15H30NO8P (383.17089500000003)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
BAY1125976
BAY1125976 is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.
CC214-2
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2]. CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2].
Dehydrocorydaline (hydroxyl)
Dehydrocorydaline (13-Methylpalmatine) hydroxyl is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline hydroxyl elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline hydroxyl shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90\%) using P. falciparum 3D7 strain.
Usmarapride (free base)
Usmarapride (SUVN-D4010) free base is a potent, selective, orally active and brain penetrant 5-HT4 receptor partial agonist (EC50=44 nM). Usmarapride (SUVN-D4010) free base can be used for the research of cognitive deficits associated with Alzheimer's disease[1].
methyl 18-formyl-19-hydroxy-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate
C23H29NO4 (383.20964740000005)
(1r,4s,5r,6r,7r,11z)-4-ethyl-5,7-dihydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
[7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 3-(acetyloxy)-2-hydroxy-2-isopropylbutanoate
n-[(2s,3s,4s,5r,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]ethanimidic acid
9-hydroxy-9-(1-hydroxyethyl)-7-(hydroxymethyl)-5-methyl-3,6,11-trioxa-15-azatetracyclo[10.5.1.0⁵,⁷.0¹⁵,¹⁸]octadec-1(17)-ene-4,10-dione
1-(2-hydroxy-1-methoxypropyl)-3-methoxy-2-methyl-6-(3-methylbut-2-en-1-yl)-9h-carbazol-4-ol
C23H29NO4 (383.20964740000005)
7-(hepta-1,3,5-trien-1-yl)-2,6,8-trioxatricyclo[5.3.1.0⁴,¹¹]undecan-4-yl 2-aminobenzoate
(1s,2s,4s,9s,10r)-14-oxo-7,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadecan-4-yl 2-aminobenzoate
C22H29N3O3 (383.22088040000006)
(3s,4s)-3-methoxy-4-(4-methoxyphenyl)-6-(3-methylbut-2-en-1-yl)-3h-quinoline-2,4,5-triol
4-({2-imino-5-[(4-methoxyphenyl)methyl]-3-methyl-1h-imidazol-4-yl}methyl)-2,6-dimethoxyphenol
methyl (1s,12r,14s,15e,18s)-12-amino-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
C22H29N3O3 (383.22088040000006)
3-[2-(7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl)-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one
C20H30ClNO4 (383.18632500000007)
n-[2-(4-{[(2e)-3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbut-2-enimidic acid
C23H29NO4 (383.20964740000005)
1-hydroxy-3,5,6-trimethoxy-10-methyl-4-(3-methylbut-2-en-1-yl)acridin-9-one
3-{[2,6-dihydroxy-3-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one
(1r,2s,3r,5r,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate
C23H29NO4 (383.20964740000005)
(3s,5r,8r,14s,18r)-5,7-dimethyl-12-methylidene-10,16-dioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate
C23H29NO4 (383.20964740000005)
dimethyl(2-{1,2,3-trimethoxy-9h-phenanthro[2,3-d][1,3]dioxol-4-yl}ethyl)amine
(1s,9r,14s)-15-hydroxy-2,11-dimethoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one
methyl (1r,3r,4r,10s,14s,15r,18r,19r)-18-formyl-19-hydroxy-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate
C23H29NO4 (383.20964740000005)
methyl (1r,2s,3r,5r,6s,10s)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-13(20),17-diene-18-carboxylate
C23H29NO4 (383.20964740000005)
(7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl)methyl 2-hydroxy-2-isopropyl-3-[(3-methylbutanoyl)oxy]butanoate
C20H33NO6 (383.23077580000006)
8-[4-(1h-indol-3-yl)-2-oxobut-3-en-1-ylidene]-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one
4-(hydroxymethyl)-7-methyl-8-[3-methyl-3-(3-methylpentyl)oxiran-2-yl]-9h-carbazole-1,6-diol
C23H29NO4 (383.20964740000005)
(3r,3as,9as)-9a-methyl-3-octanoyl-6-[(1e)-prop-1-en-1-yl]-3h,3ah,4h-furo[3,2-g]isoquinoline-2,9-dione
C23H29NO4 (383.20964740000005)
n-[2-(4-{[3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbut-2-enimidic acid
C23H29NO4 (383.20964740000005)
7-{[(2,3-dihydroxy-2-isopropylbutanoyl)oxy]methyl}-hexahydro-1h-pyrrolizin-1-yl 2-methylbut-2-enoate
C20H33NO6 (383.23077580000006)
(1s,4s,7s,11r)-7-[(1e,3e,5e)-hepta-1,3,5-trien-1-yl]-2,6,8-trioxatricyclo[5.3.1.0⁴,¹¹]undecan-4-yl 2-aminobenzoate
13-(isopropoxymethyl)-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),17(22),18,20-nonaen-12-one
n-[(3s,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]ethanimidic acid
(12s,16s,17s,19r,20s)-17,22-dihydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione
(6r,7r)-6',7'-dimethoxy-2',6-dimethyl-2,3',4',8-tetrahydrospiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-6-ol
(1r,2s,3r,5r,6s,8r,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate
C23H29NO4 (383.20964740000005)
(5s,7r,9r,12r,18r)-9-hydroxy-9-[(1s)-1-hydroxyethyl]-7-(hydroxymethyl)-5-methyl-3,6,11-trioxa-15-azatetracyclo[10.5.1.0⁵,⁷.0¹⁵,¹⁸]octadec-1(17)-ene-4,10-dione
4-[(2e,4e,6e)-8-ethyl-1,9-dihydroxynona-2,4,6-trien-1-ylidene]-5-hydroxy-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
(4z)-4-[(2e,4e,6e)-8-ethyl-1,9-dihydroxynona-2,4,6-trien-1-ylidene]-5-hydroxy-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
methyl 12-amino-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
C22H29N3O3 (383.22088040000006)
2-(3,4-dimethoxyphenyl)-5,8-dimethoxy-3-propyl-1h-quinolin-4-one
3-{[2,6-dihydroxy-3-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one
(4as,6s,7r,7as)-4-(methoxycarbonyl)-7-methyl-1h,2h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyridin-6-yl (1s)-1-methyl-1,2-dihydro-2,7-naphthyridine-4-carboxylate
(1s,4r,5s,6s,9r,10r,13r)-6-hydroxy-5,9-dimethyl-12-oxo-14-azapentacyclo[11.7.1.0¹,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-15,17,19-triene-5-carboxylic acid
C23H29NO4 (383.20964740000005)
(1r,2s,12s,15s)-7-methoxy-12-(2-methylprop-1-en-1-yl)-10,13,19-triazapentacyclo[11.7.0.0³,¹¹.0⁴,⁹.0¹⁵,¹⁹]icosa-3(11),4,6,8-tetraene-1,2-diol
C22H29N3O3 (383.22088040000006)
(1r,7s,7as)-7-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-hexahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate
C20H33NO6 (383.23077580000006)
4-(methoxycarbonyl)-7-methyl-1h,2h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyridin-6-yl 1-methyl-1,2-dihydro-2,7-naphthyridine-4-carboxylate
n-[(4-{[(2s,3r,4s,5r,6s)-5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid
[(7r,7ar)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate
9a-methyl-3-octanoyl-6-(prop-1-en-1-yl)-3h,3ah,4h-furo[3,2-g]isoquinoline-2,9-dione
C23H29NO4 (383.20964740000005)
6',7'-dihydroxy-6'-(hydroxymethyl)-3,7'-dimethyl-2',9'-dioxa-14'-azaspiro[oxirane-2,4'-tricyclo[9.5.1.0¹⁴,¹⁷]heptadecan]-11'-ene-3',8'-dione
2-[(3e,5e)-3,5-dimethyl-6-(4-nitrophenyl)hexa-3,5-dien-1-yl]-6-methoxy-3,5-dimethylpyran-4-one
(1'r,2r,3r,6'r,7's,17'r)-6',7'-dihydroxy-6'-(hydroxymethyl)-3,7'-dimethyl-2',9'-dioxa-14'-azaspiro[oxirane-2,4'-tricyclo[9.5.1.0¹⁴,¹⁷]heptadecan]-11'-ene-3',8'-dione
[(2s,3s,5r,8r)-5,9,9-trimethyl-19-oxo-4,10-dioxa-18-azapentacyclo[9.8.0.0²,⁸.0³,⁵.0¹²,¹⁷]nonadeca-1(11),12,14,16-tetraen-18-yl]methyl acetate
4-ethyl-5,7-dihydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
6',7'-dimethoxy-2',6-dimethyl-2,3',4',8-tetrahydrospiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-6-ol
(1r,3s,5r,8r,9s,11s,14s,17r,18r)-5,7-dimethyl-12-methylidene-10,16-dioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate
C23H29NO4 (383.20964740000005)
(12bs)-3,4,10,11-tetramethoxy-13,13-dimethyl-5,7,8,12b-tetrahydro-6-azatetraphene
C23H29NO4 (383.20964740000005)
4-(8-ethyl-1,9-dihydroxynona-2,4,6-trien-1-ylidene)-5-hydroxy-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
(3r)-3-[(1s)-2-[(1r,3s,4as,7s,8ar)-7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one
C20H30ClNO4 (383.18632500000007)
(12s,16r,17s,19r,20s)-17,22-dihydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione
(3r)-3-[(1s)-2-[(1r,3s,4as,7s,8as)-7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one
C20H30ClNO4 (383.18632500000007)
4,6-dihydroxy-2',5',5',8'a-tetramethyl-2',3,3',4',4'a,7',8,8'-octahydrospiro[furo[2,3-e]isoindole-2,1'-naphthalen]-6'-one
C23H29NO4 (383.20964740000005)
tert-butyl 3-{[(3s,8as)-1-hydroxy-4-oxo-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-3-yl]methyl}indole-1-carboxylate
6-({2-imino-5-[(4-methoxyphenyl)methyl]-3-methyl-1h-imidazol-4-yl}methyl)-2,3-dimethoxyphenol
(3s,8as)-3-{[(3s)-2,6-dihydroxy-3-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one
(1r,2s,3r,5r,6s,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate
C23H29NO4 (383.20964740000005)
[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r,3r)-2-hydroxy-2-isopropyl-3-[(3-methylbutanoyl)oxy]butanoate
C20H33NO6 (383.23077580000006)
(2s,3s,4r,5s,6r)-2-(hydroxymethyl)-6-({[(2r)-4-(3h-purin-6-ylamino)butan-2-yl]oxy}methyl)oxane-3,4,5-triol
4,5,14,15,16-pentamethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,13,15-heptaene
(2r,2'r,4'ar,8'as)-4,6-dihydroxy-2',5',5',8'a-tetramethyl-2',3,3',4',4'a,7',8,8'-octahydrospiro[furo[2,3-e]isoindole-2,1'-naphthalen]-6'-one
C23H29NO4 (383.20964740000005)
15-hydroxy-2,11-dimethoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one
(7s,8z)-8-[(3e)-4-(1h-indol-3-yl)-2-oxobut-3-en-1-ylidene]-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one
17,22-dihydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione
methyl (1s,2s,3s,5s,10r)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-13(20),17-diene-18-carboxylate
C23H29NO4 (383.20964740000005)
n-[(4-{[5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid
3-methoxy-4-(4-methoxyphenyl)-6-(3-methylbut-2-en-1-yl)-3h-quinoline-2,4,5-triol
(3s,8as)-3-{[(3s)-2,6-dihydroxy-3-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one
(3r,4r)-3-methoxy-4-(4-methoxyphenyl)-6-(3-methylbut-2-en-1-yl)-3h-quinoline-2,4,5-triol
{5,9,9-trimethyl-19-oxo-4,10-dioxa-18-azapentacyclo[9.8.0.0²,⁸.0³,⁵.0¹²,¹⁷]nonadeca-1(11),12,14,16-tetraen-18-yl}methyl acetate
(3r)-3-[(1s)-2-[(1s,4r,4as,7s,8ar)-7-chloro-4-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one
C20H30ClNO4 (383.18632500000007)
(3s,6s)-3-[(2r)-3-hydroxy-2-methylpropyl]-6-{[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol
C22H29N3O3 (383.22088040000006)